Pam R Taub1, Adena Zadourian2, Hannah C Lo3, Cameron K Ormiston3, Shahrokh Golshan4, Jonathan C Hsu5. 1. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, California, USA. Electronic address: ptaub@health.ucsd.edu. 2. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, California, USA. Electronic address: https://twitter.com/AdenaZadourian. 3. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, California, USA. 4. Department of Psychiatry, University of California, San Diego, California, USA. 5. Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, California, USA. Electronic address: https://twitter.com/JonHsuMD.
Abstract
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is a complex, multifaceted disorder that impairs functional status and quality of life. Current pharmacological treatments are limited. OBJECTIVES: This study investigated the effect of ivabradine (selective blocker of the Ifunny channel in the sinoatrial node) on heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels in patients with hyperadrenergic POTS defined by plasma NE >600 pg/ml and abnormal tilt table test. METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were crossed over to the other treatment for 1 month. Heart rate, QOL, and plasma NE levels were measured at baseline and at the end of each treatment month. RESULTS:The average age was 33.9 ± 11.7 years, 95.5% were women (n = 21), and 86.4% were White (n = 23). There was a significant reduction in heart rate between placebo and ivabradine (p < 0.001). Patients reported significant improvements in QOL with RAND 36-Item Health Survey 1.0 for physical functioning (p = 0.008) and social functioning (p = 0.021). There was a strong trend in reduction of NE levels upon standing with ivabradine (p = 0.056). Patients did not experience any significant side-effects, such as bradycardia or hypotension, with ivabradine. CONCLUSION: Ivabradine is safe and effective in significantly improving heart rate and QOL in patients with hyperadrenergic POTS as the predominant subtype.
RCT Entities:
BACKGROUND:Postural orthostatic tachycardia syndrome (POTS) is a complex, multifaceted disorder that impairs functional status and quality of life. Current pharmacological treatments are limited. OBJECTIVES: This study investigated the effect of ivabradine (selective blocker of the Ifunny channel in the sinoatrial node) on heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels in patients with hyperadrenergic POTS defined by plasma NE >600 pg/ml and abnormal tilt table test. METHODS: In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were crossed over to the other treatment for 1 month. Heart rate, QOL, and plasma NE levels were measured at baseline and at the end of each treatment month. RESULTS: The average age was 33.9 ± 11.7 years, 95.5% were women (n = 21), and 86.4% were White (n = 23). There was a significant reduction in heart rate between placebo and ivabradine (p < 0.001). Patients reported significant improvements in QOL with RAND 36-Item Health Survey 1.0 for physical functioning (p = 0.008) and social functioning (p = 0.021). There was a strong trend in reduction of NE levels upon standing with ivabradine (p = 0.056). Patients did not experience any significant side-effects, such as bradycardia or hypotension, with ivabradine. CONCLUSION:Ivabradine is safe and effective in significantly improving heart rate and QOL in patients with hyperadrenergic POTS as the predominant subtype.
Authors: Kenneth A Mayuga; Artur Fedorowski; Fabrizio Ricci; Rakesh Gopinathannair; Jonathan Walter Dukes; Christopher Gibbons; Peter Hanna; Dan Sorajja; Mina Chung; David Benditt; Robert Sheldon; Mirna B Ayache; Hiba AbouAssi; Kalyanam Shivkumar; Blair P Grubb; Mohamed H Hamdan; Stavros Stavrakis; Tamanna Singh; Jeffrey J Goldberger; James A S Muldowney; Mark Belham; David C Kem; Cem Akin; Barbara K Bruce; Nicole E Zahka; Qi Fu; Erik H Van Iterson; Satish R Raj; Fetnat Fouad-Tarazi; David S Goldstein; Julian Stewart; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2022-09-08
Authors: Ty J Gluckman; Nicole M Bhave; Larry A Allen; Eugene H Chung; Erica S Spatz; Enrico Ammirati; Aaron L Baggish; Biykem Bozkurt; William K Cornwell; Kimberly G Harmon; Jonathan H Kim; Anuradha Lala; Benjamin D Levine; Matthew W Martinez; Oyere Onuma; Dermot Phelan; Valentina O Puntmann; Saurabh Rajpal; Pam R Taub; Amanda K Verma Journal: J Am Coll Cardiol Date: 2022-03-16 Impact factor: 27.203
Authors: Cameron K Ormiston; Erika Padilla; David T Van; Christine Boone; Sophie You; Anne C Roberts; Albert Hsiao; Pam R Taub Journal: Eur Heart J Case Rep Date: 2022-04-09